Pfizer wins fast track status; OncoPep raises $6.9M for cancer vaccine;

@FierceBiotech: FDA lifts a hold on one of OncoMed's cancer drug programs. Article | Follow @FierceBiotech

@JohnCFierce: Trending today - What's the #1 biotech hub for VCs? (It's still not Boston). Story | Follow @JohnCFierce

@EmilyMFierce: Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. More | Follow @EmilyMFierce

> The FDA has granted Pfizer ($PFE) its fast track designation to the company's investigational Clostridium difficile (C. difficile) vaccine candidate PF-06425090. Release

> Boston-based OncoPep has raised $6.9 million for a Series B round. The money will be used to back its lead cancer vaccine, PVX-410, which is designed to target tumor antigens associated with multiple myeloma. Release

Medical Device News

@FierceMedDev: ReShape targets U.S. approval as EU study shows major weight loss. More | Follow @FierceMedDev

@VarunSaxena2: Between new Brain project initiative and 2 recent $COV buys + $BSX's buy of Bayer's devices, peripheral devices are officially a thing. | Follow @VarunSaxena2

@EmilyWFierce: Covidien snatched up venous disease treatment developer Sapheon for an undisclosed sum. Story | Follow @EmilyWFierce

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Article | Follow @MichaelGFierce

> J&J's DePuy Synthes unit slapped with FDA Class I recall for jaw-stabilizing device. More

> Biomarker could improve early rheumatoid arthritis diagnosis. News

> ReShape targets U.S. approval as EU study shows major weight loss. Story

Pharma News

@FiercePharma: Mutated poliovirus found to beat vaccine protection. Article | Follow @FiercePharma

@EricPFierce: CPhI Worldwide will host #CPhIChat to debate the future of pharma for those of you who want a piece of that. Release | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Does Pfizer still need AstraZeneca's vaccines business? Story | Follow @CarlyHFierce

> U.K.'s cancer drugs fund gets £160M--and power to push for lower prices. Article

> Valeant, Ackman score a chance to force Allergan to an earlier showdown. Story

> Novartis takes a cue from GSK, Biogen with wide-open spaces in new Aussie HQ. News

Vaccines News

> Glaxo's Ebola vaccine trial set to begin in September. Article

> Does Pfizer still need AstraZeneca's vaccines business? Story

> Advaxis teams up with Merck to test its vaccine in prostate cancer. More

> Diamyd diabetes vax, once spurned by J&J, gets an EU boost. Report

> Mutated polio virus found to beat vaccine protection. Story

Pharma Manufacturing News

> NAFTA says FDA was in its rights to ban Apotex plants. More

> Merck KGaA starts work on what will be its second-largest plant. Article

> GSK, NewLink ramp up production of Ebola drugs, even as they conduct trials. Piece

> Patheon gets U.S. biologics plants with Gallus deal. Story

> Novo buys U.S. plant ditched by Olympus. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.